Voruciclib hydrochloride

• CAT Number: I019169
• CAS Number: 1000023-05-1
• Molecular Formula: C₂₂H₂₀Cl₂F₃NO₅
• Molecular Weight: 506.30
• Purity: ≥95%
• IUPAC Name: 2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one;hydrochloride
• InChI: InChI=1S/C22H19ClF3NO5.ClH/c1-27-5-4-12(14(27)9-28)19-15(29)7-16(30)20-17(31)8-18(32-21(19)20)11-3-2-10(6-13(11)23)22(24,25)26;/h2-3,6-8,12,14,28-30H,4-5,9H2,1H3;1H/t12-,14+;/m1./s1
• InChIKey: QCWRANLELLMJSH-OJMBIDBESA-N
• SMILES: CN1CC[C@H]([C@@H]1CO)C2=C(C=C(C3=C2OC(=CC3=O)C4=C(C=C(C=C4)C(F)(F)F)Cl)O)O.Cl

Voruciclib hydrochloride（Cat No.:I019169） is a small-molecule inhibitor of cyclin-dependent kinases (CDKs) that has potential anticancer activity. It selectively inhibits CDK4 and CDK6, enzymes that regulate the cell cycle and play a crucial role in cell proliferation. Voruciclib hydrochloride has been shown to induce G1 cell cycle arrest and reduce tumor cell growth in preclinical studies. It is being investigated as a potential treatment for various types of cancer, including breast cancer, mantle cell lymphoma, and acute myeloid leukemia.

Reference

[1]. Dey J, et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Sci Rep. 2017 Dec 21;7(1):18007.